PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGemcitabine
Gemcitabine
Gemcitabine (gemcitabine) is a small molecule pharmaceutical. Gemcitabine was first approved as Gemzar on 1996-05-15. It is used to treat breast neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic ductal carcinoma in the USA. The pharmaceutical is active against ribonucleoside-diphosphate reductase large subunit and ribonucleoside-diphosphate reductase subunit M2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Gemcitabine (discontinued: Gemcitabine, Gemzar, Infugem)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gemcitabine hydrochloride
Tradename
Company
Number
Date
Products
GEMCITABINE HYDROCHLORIDEAccord HealthcareN-209604 RX2017-08-03
4 products, RLD, RS
GEMCITABINE HYDROCHLORIDEHospiraN-200795 RX2011-08-04
3 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
avgemsiNew Drug Application2025-07-20
gemcitabineANDA2025-07-23
gemcitabine gemcitabineANDA2019-09-12
gemcitabine hydrochlorideANDA2025-01-09
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Gemcitabine Hydrochloride, Infugem, Sun Pharm
92419482033-07-01DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01B: Antimetabolites
L01BC: Pyrimidine analogues, antineoplastic antimetabolites
L01BC05: Gemcitabine
HCPCS
Code
Description
J9198
Injection, gemcitabine hydrochloride, (infugem), 100 mg
J9201
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
Clinical
Clinical Trials
3427 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C253636161335881038
Non-small-cell lung carcinomaD002289782421061221421
Lung neoplasmsD008175C34.906423085919375
CarcinomaD002277C80.066213102224373
AdenocarcinomaD00023011920737219327
NeoplasmsD009369C802421142128325
LymphomaD008223C85.9771564079250
Breast neoplasmsD001943EFO_0003869C504614272110244
Urinary bladder neoplasmsD001749C674713945218222
CholangiocarcinomaD018281C22.14312929115194
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD01250934527381
Large b-cell lymphoma diffuseD016403C83.3244715174
B-cell lymphomaD016393314615173
Gallbladder neoplasmsD005706EFO_0004606C23174516573
Non-hodgkin lymphomaD008228C85.928379164
Fallopian tube neoplasmsD00518519291456
Liver neoplasmsD008113EFO_1001513C22.0132810549
Kidney neoplasmsD007680EFO_0003865C6410322142
Ureteral neoplasmsD014516EFO_0003844C6611274138
Bile duct neoplasmsD00165011227137
Show 102 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151793435559
Stomach neoplasmsD013274EFO_0003897C16158423
Esophageal neoplasmsD004938C15106216
MelanomaD008545107215
LeukemiaD007938C9568114
Endometrial neoplasmsD016889EFO_000423081014
Multiple myelomaD009101C90.051012
Ewing sarcomaD012512EFO_0000173199
Plasma cell neoplasmsD054219188
B-cell chronic lymphocytic leukemiaD015451C91.1547
Show 126 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pseudomyxoma peritoneiD011553EFO_0007456112
Skin neoplasmsD012878EFO_0004198C44112
Diffuse intrinsic pontine gliomaD00008044322
Connective and soft tissue neoplasmsD01820411
Pharyngeal neoplasmsD010610C14.011
Rhabdoid tumorD01833511
MeningiomaD008579EFO_0003098D32.911
EpendymomaD00480611
AstrocytomaD001254EFO_000027111
Choroid plexus neoplasmsD016545EFO_000720611
Show 16 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PrognosisD01137922
Acute diseaseD00020811
Multiple primary neoplasmsD00937811
Brain deathD001926G93.8211
AscitesD001201R1811
Appendiceal neoplasmsD001063EFO_0003880C18.111
Pleural neoplasmsD01099711
Maintenance chemotherapyD06004611
Liver transplantationD016031EFO_001068211
HypoxiaD000860R09.0211
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGemcitabine
INNgemcitabine
Description
Gemcitabine is a 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It has a role as a photosensitizing agent, a DNA synthesis inhibitor, a prodrug, an EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, an environmental contaminant, a xenobiotic, a radiosensitizing agent, an antineoplastic agent, an antimetabolite, an antiviral drug and an immunosuppressive agent. It is an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside.
Classification
Small molecule
Drug classnucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Identifiers
PDB
CAS-ID95058-81-4
RxCUI
ChEMBL IDCHEMBL888
ChEBI ID175901
PubChem CID60750
DrugBankDB00441
UNII IDB76N6SBZ8R (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 96,271 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
59,360 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use